Key result
Measurement of C-reactive protein may add predictive accuracy to the Framingham risk score, allowing reclassification of low or intermediate risk patients to a higher risk category.
Why the study?
Does measurement of C-reactive protein improve predictive accuracy in primary prevention patients?
Does measurement of C-reactive protein improve predictive accuracy in primary prevention patients?
CRP measurement can improve cardiovascular risk stratification by reclassifying low or intermediate-risk primary prevention patients into higher risk categories, making them eligible for more intensive pharmacologic interventions.
May support CRP for reclassifying primary prevention risk; leaves open prospective validation before practice change.
C-reactive protein (CRP) is an inflammatory biomarker that is strongly associated with coronary heart disease, inflammation, and the metabolic syndrome. Large-scale prospective cohort trials have shown that measurement of CRP may add predictive accuracy to the Framingham risk score, but interpretation of these data are conflicting. In the primary prevention setting, CRP can be used to reclassify patients in low or intermediate Framingham risk score groups to a higher risk category, thus making them eligible for more intensive pharmacologic interventions.
No takes yet. Share an insight, caveat, or question.
Abraham et al. (2007) conducted a review in Cardiovascular risk. C-reactive protein (CRP) measurement was evaluated. Measurement of C-reactive protein may add predictive accuracy to the Framingham risk score, allowing reclassification of low or intermediate risk patients to a higher risk category.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: